Clinical outcomes and safety study of CDK4/6 inhibitors in hormone-positive metastatic breast cancer - A real-world tertiary cancer center experience
CDK4/6 inhibitors demonstrate similar responses and better tolerance in real-world evidence. Further studies are necessary to identify other predictive and resistance factors for the use of CDK4/6 inhibitors.
Authors
- Sandhya Appachu
- Ravi B. Diwaker
- Sai Vivek
- Vijai V. S. Simha
- K. S. Sandeep
Institutions
- HCG Cancer Hospital (IN)
- Cancer Clinic (US)
- Nethradhama Superspeciality Eye Hospital (IN)
- Sri Shankara Cancer Hospital and Research Center
Publication Details
- Journal
- Indian Journal of Cancer
- Published
- 2025-10-01
- DOI
- https://doi.org/10.4103/ijc.ijc_643_23
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00